Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis

Xinxin Zhong; Ao Lin; Jian Luo; Yeqin Li; Jinlan Chen; Chao Ning; Fu Cao

doi:10.1093/postmj/qgad140

Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis

Postgrad Med J. 2024 May 18;100(1184):366-372. doi: 10.1093/postmj/qgad140.

Authors

Xinxin Zhong¹, Ao Lin², Jian Luo¹, Yeqin Li¹, Jinlan Chen¹, Chao Ning¹, Fu Cao¹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Red Cross Hospital of Yulin City, Yulin, Guangxi 537000, China.
² Department of Cardiothoracic Surgery, Red Cross Hospital of Yulin City, Yulin, Guangxi 537000, China.

PMID: 38200633
DOI: 10.1093/postmj/qgad140

Abstract

Multidrug-resistant tuberculosis (MDR-TB) has become a critical challenge to public health, and the prevention and treatment of MDR-TB are of great significance in reducing the global burden of tuberculosis. How to improve the effectiveness and safety of chemotherapy for MDR-TB is a pressing issue that needs to be addressed in tuberculosis control efforts. This article provides a comprehensive review of the clinical application of new antituberculosis drugs in MDR-TB, aiming to provide a scientific basis for the prevention and treatment strategy of MDR-TB.

Keywords: antituberculosis drugs; chemotherapy; multidrug-resistance; mycobacterium.

Publication types

Review

MeSH terms

Antitubercular Agents* / therapeutic use
Humans
Mycobacterium tuberculosis / drug effects
Tuberculosis, Multidrug-Resistant* / drug therapy

Grants and funding

202235090/Science and Technology Bureau of Yulin City